EANS-Adhoc: Intercell announces next steps of development for Pseudomonas vaccine

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Research & Development

01.04.2011

Vienna (Austria), April 1, 2011 - Today Intercell AG (VSE: ICLL)
announced that it has agreed with Novartis to advance Intercell's
investigational Pseudomonas aeruginosa vaccine into a confirmatory
clinical efficacy trial in ventilated ICU (Intensive Care Unit)
patients. The planned double blind study is powered to show a
clinically meaningful and statistically significant reduction in
overall mortality between the vaccine and control group and envisages
enrolling about 800 subjects. The study is subject to final
regulatory concurrence and its start is planned for first half of
2012. Intercell will execute the trial and the costs will be shared
with Novartis.

Intercell's Pseudomonas aeruginosa vaccine program is one of the
development programs under the strategic alliance between Intercell
and Novartis. Next steps for the program will be decided based upon
data from the planned efficacy trial, taking into consideration the
Novartis option rights and the Intercell right to choose either
profit-sharing or to receive milestones and royalties. "Pseudomonas
infections are a major cause of mortality in artificially ventilated
ICU patients. Our Phase II data showed a statistically significant
improved survival of patients vaccinated and we are happy that we
will together with Novartis move the program forward. This further
strongly underlines our leading position to develop vaccines against
hospital acquired infections, one of the major medical problems in
global societies", states Gerd Zettlmeissl, Chief Executive Officer
of Intercell.

The trial is expected to be conducted in various countries,
predominantly in the EU, involving up to 50 study sites. Two study
groups, both receiving standard of care in addition to vaccine or
placebo, will be compared. The subjects in the vaccine group which
will comprise about 400 ventilated ICU patients will be vaccinated
twice within a 7-day interval with the non-adjuvanted product
formulation that was found to most impact observed survival. Primary
endpoint of the trial will be mortality at day 28 after first
vaccination in both study groups. Secondary objectives are to
investigate Pseudomonas aeruginosa infections, infection-related
mortality as well as immune response to the vaccine candidate and its
safety and tolerability.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market